InnoCare Pharma Ltd
SSE:688428
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.3
11.78
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one InnoCare Pharma Ltd stock under the Base Case scenario is 4.11 CNY. Compared to the current market price of 11.33 CNY, InnoCare Pharma Ltd is Overvalued by 64%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
InnoCare Pharma Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for InnoCare Pharma Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
InnoCare Pharma Ltd
Balance Sheet Decomposition
InnoCare Pharma Ltd
Current Assets | 9.3B |
Cash & Short-Term Investments | 9.1B |
Receivables | 144.6m |
Other Current Assets | 101.4m |
Non-Current Assets | 1B |
Long-Term Investments | 11.7m |
PP&E | 696.5m |
Intangibles | 276.3m |
Other Non-Current Assets | 44.6m |
Current Liabilities | 2.1B |
Accounts Payable | 118.6m |
Accrued Liabilities | 57m |
Other Current Liabilities | 1.9B |
Non-Current Liabilities | 664m |
Long-Term Debt | 35.4m |
Other Non-Current Liabilities | 628.6m |
Earnings Waterfall
InnoCare Pharma Ltd
Revenue
|
625.4m
CNY
|
Cost of Revenue
|
-143.4m
CNY
|
Gross Profit
|
482m
CNY
|
Operating Expenses
|
-1.2B
CNY
|
Operating Income
|
-730.9m
CNY
|
Other Expenses
|
-155.7m
CNY
|
Net Income
|
-886.6m
CNY
|
Free Cash Flow Analysis
InnoCare Pharma Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
InnoCare Pharma Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
InnoCare Pharma Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
InnoCare Pharma Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
InnoCare Pharma Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
InnoCare Pharma Ltd
According to Wall Street analysts, the average 1-year price target for InnoCare Pharma Ltd is 14.64 CNY with a low forecast of 14.14 CNY and a high forecast of 15.44 CNY.
Shareholder Yield
Current shareholder yield for InnoCare Pharma Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Price
InnoCare Pharma Ltd
Average Annual Return | 58.52% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -56% |
Market Capitalization | 9.6B CNY |
Shares Outstanding | 844 306 335 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
InnoCare Pharma Ltd. is a clinical-stage biopharmaceutical company. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-03-23. The firm discovers, develops and commercializes potentially best-in-class and first-in-class drugs for the treatment of cancer and autoimmune diseases. The firm builds a fully integrated biopharmaceutical platform with strong in-house research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.
Contact
IPO
Employees
Officers
The intrinsic value of one InnoCare Pharma Ltd stock under the Base Case scenario is 4.11 CNY.
Compared to the current market price of 11.33 CNY, InnoCare Pharma Ltd is Overvalued by 64%.